Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE1
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
- Status
- TERMINATED
- Phase
- PHASE2
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Status
- UNKNOWN
- Phase
- PHASE3
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- Status
- TERMINATED
- Phase
- PHASE1
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
- Status
- RECRUITING
- Phase
- PHASE2
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations
- Status
- RECRUITING
- Phase
- NA
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Status
- TERMINATED
- Phase
- PHASE3
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
- Status
- RECRUITING
- Phase
- PHASE1
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3